| Literature DB >> 35977720 |
Loïc Epelboin1,2, Aba Mahamat1,3, Timothée Bonifay4, Magalie Demar1,2,5, Philippe Abboud1,2, Gaëlle Walter1, Anne-Sophie Drogoul6, Alain Berlioz-Arthaud6, Mathieu Nacher7, Didier Raoult8, Félix Djossou1,2, Carole Eldin9.
Abstract
In French Guiana, community-acquired pneumonia (CAP) represents over 90% of Coxiella burnetii acute infections. Between 2004 and 2007, we reported that C. burnetii was responsible for 24.4% of the 131 CAP hospitalized in Cayenne. The main objective of the present study was to determine whether the prevalence of Q fever pneumonia remained at such high levels. The secondary objectives were to identify new clinical characteristics and risk factors for C. burnetii pneumonia. A retrospective case-control study was conducted on patients admitted in Cayenne Hospital, between 2009 and 2012. All patients with CAP were included. The diagnosis of acute Q fever relied on titers of phase II IgG ≥ 200 and/or IgM ≥ 50 or seroconversion between two serum samples. Patients with Q fever were compared with patients with non-C. burnetii CAP in bivariate and multivariate analyses. During the 5-year study, 275 patients with CAP were included. The etiology of CAP was identified in 54% of the patients. C. burnetii represented 38.5% (106/275; 95% CI: 31.2-45.9%). In multivariate analysis, living in Cayenne area, being aged 30-60 years, C-reactive protein (CRP) > 185 mg/L, and leukocyte count < 10 G/L were independently associated with Q fever. The prevalence of Q fever among CAP increased to 38.5%. This is the highest prevalence ever reported in the world. This high prevalence justifies the systematic use of doxycycline in addition to antipneumococcal antibiotic regimens.Entities:
Mesh:
Year: 2022 PMID: 35977720 PMCID: PMC9393466 DOI: 10.4269/ajtmh.21-0711
Source DB: PubMed Journal: Am J Trop Med Hyg ISSN: 0002-9637 Impact factor: 3.707
Baseline characteristics and comparison of sociodemographical features between cases and controls
| Characteristics | Variables | Q fever CAP ( | Non-Q fever CAP ( | All CAP ( | OR (95% CI) | |
|---|---|---|---|---|---|---|
| Age | Mean (±SD) (years) | 47.3 (±13.4) | 46.4 (±18.1) | 46.8 (±16.4) | – | NS |
| Age 30–60 years vs. others | 76 (71.7) | 94 (55.6) | 179 (65) | 2.02 (1.17–3.53) | 0.008 | |
| Gender | Male sex | 70 (66) | 96 (56) | 166 (60) | 1.48 (0.87–2.53) | 0.13 |
| Sex ratio M/F | 1.9 | 1.3 | 1.5 | – | – | |
| Country/region of birth | Mainland France | 32/102 (30.2) | 32/164 (19.5) | 64 (23) | 1.89 (1.02–3.47) | 0.03 |
| French Guiana | 48/102 (47.1) | 65/164 (39.6) | 113 (41) | 1.36 (0.80–2.30) | 0.23 | |
| Brazil | 7/102 (6.9) | 24/164 (14.6) | 31 (11.2) | 0.43 (0.18–1.02) | 0.05 | |
| Other | 15/102 (14.7) | 43/164 (26.2) | 58 (21) | 0.49 (0.26–0.92) | 0.03 | |
| Place of residence | Cayenne | 41/102 (40.2) | 73/166 (44.0) | 114 (42.5) | 0.86 (0.50–1.45) | 0.54 |
| Rémire-Montjoly | 30/102 (29.4) | 30/166 (18.1) | 60/268 (22.4) | 1.89 (1.06–3.37) | 0.03 | |
| Matoury | 26/102 (25.5) | 30/166 (18.1) | 56/268 (20.9) | 1.55 (0.82–2.93) | 0.15 | |
| Cayenne area¤ | 100/106 (94.3) | 140/169 (82.8%) | 240/275 (85.8) | 4.8 (1.8–16.2) | < 0.001 | |
| Comorbidities | Sickle cell disease | 0/84 (0) | 13/155 (8.4) | 13 (5) | – | 0.006 |
| Tobacco smoking | 52/100 (52) | 48/168 (28.6) | 100 (36.3) | 2.71 (1.57–4.69) | < 0.001 | |
| Cannabis smoking | 5 (4.7) | 5 (3) | 10 (3.6) | 1.62 (0.36–7.23) | 0.45 | |
| Crack smoking | 1/101 (1) | 7/168 (4) | 8 (3) | 0.23 (0.01–1.84) | 0.14 | |
| Alcohol | 54/100 (54.0) | 65/168 (38.7) | 119 (43.2) | 1.86 (1.09–3.17) | 0.015 | |
| PLHIV | 1/90 (1.1) | 6/149 (3.9) | 7 (2) | 0.28 (0.01–2.34) | 0.21 | |
| Environmental exposure | Leveling work near the house | 27/88 (25.4) | 20/168 (11.8) | 47 (17.4) | 4.23 (2.13–8.45) | < 0.001 |
| Gardening | 23 (26.1) | 19 (11.3) | 42 (15.2) | 4.70 (2.46–9.12) | < 0.001 |
CAP = community-acquired pneumonia; NS = not significant; PLHIV = people living with human immunodeficiency virus; OR = odds ratio. Cayenne area = Cayenne + Rémire-Montjoly + Matoury.
P value obtained by bivariate logistic regression.
Etiology of community-acquired pneumonias admitted in the department of infectious and tropical diseases, Cayenne Hospital, French Guiana, 2009–2012
| Microbiological agent associated with CAP | |
|---|---|
|
| 106 (38.5) |
|
| 21 (7.6) |
|
| 5 (1.8) |
| 4 (1.5) | |
| Dengue virus | 2 (0.7) |
| 2 (0.7) | |
|
| 2 (0.4) |
| Tuberculosis | 1 (0.4) |
|
| 1 (0.4) |
|
| 1 (0.4) |
| Epstein-Barr virus | 1 (0.4) |
|
| 1 (0.4) |
| Measles | 1 (0.4) |
| Unknown | 127 (46.2) |
| Total | 275 (100) |
CAP = community-acquired pneumonia.
Two diagnosis with blood cultures, two with S. pneumoniae urinary antigen, and one with both.
In French Guiana, infection with a virulent strain of Toxoplasma gondii in immunocompetent patients is frequent and so-called Amazonian toxoplasmosis.
Prevalence of Q fever among pneumonias admitted in the Cayenne Hospital 2009–2012 according to the year
| Year | Not Q fever | Q fever | Total | Q fever prevalence (%) | 95% CI (%) |
|---|---|---|---|---|---|
| 2009 | 5 | 11 | 16 | 68.8 | 28.1–109.4 |
| 2010 | 97 | 40 | 137 | 29.2 | 20.1–38.2 |
| 2011 | 46 | 29 | 75 | 38.7 | 24.6–52.7 |
| 2012 | 21 | 26 | 47 | 55.3 | 34.0–76.6 |
| Total | 169 | 106 | 275 | 38.5 | 31.2–45.9 |
Comparison of clinical, biological, and radiological features of Q fever patients and controls, bivariate analysis
| Clinical features | Q fever CAP ( | Non-Q fever CAP ( | All CAP ( | OR (95% CI) |
| |
|---|---|---|---|---|---|---|
| Physical examination | Temperature > 38.2 | 56/95 (59.0) | 63/155 (40.7) | 119/250 (47.6) | 2.1 (1.2–3.7) | 0.005 |
| Mean temperature (±SD) (°C) | 38.4 (±1.2) | 38.0 (±1.3) | 38.1 (±1.3) | – | 0.01 | |
| Headache | 64 (60.4) | 65/168 (38.7) | 129 (47.1) | 2.4 (1.4–4.1) | < 0.001 | |
| Chills | 51 (48.1) | 59/168 (35.1) | 110 (40.1) | 1.7 (1.1–2.8) | 0.03 | |
| Muscle pain | 55 (51.9) | 60/168 (35.7) | 115 (42.0) | 1.9 (1.2–3.2) | 0.008 | |
| Cough | 62 (58.5) | 119/168 (70.8) | 181 (66.1) | 0.6 (0.4–0.9) | 0.04 | |
| Chest pain | 24 (22.6) | 53/168 (31.5) | 77 (28.1) | 0.6 (0.4–1.1) | 0.11 | |
| Dyspnea | 14 (13.2) | 37/168 (22.0) | 51 (18.6) | 0.5 (0.3–1.1) | 0.07 | |
| Ear nose and throat symptoms | 8 (7.6) | 39/165 (23.6) | 47 (17.6) | 0.3 (0.1–0.6) | < 0.001 | |
| Abdominal pain | 16 (15.1) | 17/164 (10.4) | 33 (12.2) | 1.5 (0.8–3.2) | 0.25 | |
| Diarrhea | 14/104 (13.5) | 33/162 (20.4) | 47 (17.7) | 0.6 (0.3–1.2) | 0.15 | |
| Vomiting | 28 (26.4) | 38/163 (23.3) | 66 (24.5) | 1.2 (0.7–2.1) | 0.56 | |
| Abnormal pulmonary auscultation | 50/95 (52.6) | 129/165 (78.2) | 179/260 (68.8) | 0.3 (0.2–0.6) | < 0.001 | |
| Chest X-rays | Abnormal radiography | 63/83 (75.9) | 145/168 (86.3) | 208/251 (82.9) | 0.5 (0.2–1.0) | 0.05 |
| Laboratory results | ||||||
| Leukocytes < 10 G/L | 84/101 (83.2) | 91/163 (55.8) | 4.2 (2.1–7.6) | < 0.001 | ||
| Neutrophils < 7.7 G/L | 82/97 (84.5) | 100/162 (61.7) | 3.4 (1.7–6.9) | < 0.001 | ||
| Lymphocytes < 1 G/L | 22/95 (23.2) | 33/160 (20.6) | 1.2 (0.6–2.2) | 0.64 | ||
| CRP > 185 mg/L | 56/98 (57.1) | 57/167 (34.1) | 2.6 (1.5–4.4) | < 0.001 | ||
| Platelet count < 150 G/L | 20/96 (20.8) | 23/161 (14.3) | 1.6 (0.8–3.2) | 0.17 | ||
| SGPT and/or SGOT > 1.5 N | 48/96 (50.0) | 54/154 (35.1) | 1.9 (1.1–3.2) | 0.02 | ||
| Creatinine > 126 µM) | 5/88 (5.7) | 14/158 (8.9) | 0.6 (0.2–1.9) | 0.37 |
CRP = C-reactive protein; OR = odds ratio; SGOT = serum glutamooxaloacetate transférase; SGPT = serum glutamo pyruvate transférase.
Comparison in multivariate analysis of clinical, biological, and radiological features of Q fever patients and controls supported between 2009 and 2012 in Cayenne General Hospital, and comparison to the results of the first study 2007–2004
| Study period | 2009–2012 | 2004–2007 | ||
|---|---|---|---|---|
| Multivariate analysis | aOR | 95% CI | aOR 95% CI | 95% CI |
| To be living in Cayenne area | 3.6 | 1.3–10.0 | – | – |
| Male gender | – | – | 4.8 | 1.3–17.9 |
| Age 30–60 years | 2.1 | 1.2–3.8 | 5.0 | 1.5–16.8 |
| Headache | – | – | 4.4 | 1.6–12.4 |
| CRP > 185 mg/L | 3.1 | 1.7–5.5 | 4.1 | 1.4–11.8 |
| Leukocytes < 10 G/L | 4.54 | 2.4–8.7 | 7.3 | 1.9–27.4 |
aOR = adjusted odds ratio.
Prevalence of Coxiella burnetii among acute community-acquired pneumonia
| Continent | Region of study (city) | Name of first author | Year of publication | Study period | Patients and study category | Sample size | Prevalence of Q fever |
|---|---|---|---|---|---|---|---|
| Europe | United Kingdom (Nottingham) | Woodhead | 1987 | NK | Community | 0/236 | 0% |
| United Kingdom (5 studies) | BTS | 1981–1982–19841987–2001 | NK | In hospital | 13/1137 | 1.2% | |
| United Kingdom (4 studies) | BTS | 1985–19901992–1997 | NK | ICU | 0/185 | 0% | |
| Western Europe (6 studies: Italy, Norway, Spain, Sweden) | BTS | 1986–1991–19921993– 1995–2000 | NK | Community | 5/654 | 0.8% | |
| Western Europe (23 studies) | BTS | 2001 | NK | In hospital | 36/2026 | 0.6% | |
| Western Europe (10 studies) | BTS | 2001 | NK | ICU | 8/1148 | 0.7% | |
| France | SPILF | 2006* | Pneumonias | UK | 0% | ||
| The Netherlands (Bernhoven) | Limonard | 2012 | 2007 | In hospital | 21/95 | 22% | |
| The Netherlands (Nieuwegein) | Meijvis | 2011 | 2007–2010 | In hospital | 27/304 | 8.9% | |
| The Netherlands (Nieuwegein) | Endeman | 2008 | 2004–2006 | In hospital | 1/201 | 0.5% | |
| The Netherlands (Alkmaar) | Snijders | 2010 | 2005–2008 | In hospital | 0/213 | 0% | |
| The Netherlands (Alkmaar) | Van der Eerden | 2005 | 1998–2000 | In hospital | 0/262 | 0% | |
| The Netherlands (Tilburg) | Huijskens | 2016 | 2008–2009 | Emergency room | 50/404 | 12.3% | |
| The Netherland (Tilburg) | Huijskens | 2013 | 2008–2009 | Emergency room | 27/408 | 6.8% | |
| The Netherlands (Nieuwegein and Ede) | Spoorenberg | 2014 | 2004–2010 | In hospital | 28/505 | 5.5% | |
| Switzerland (Lausanne) | Bochud | 2001 | 1998–2000 | Outpatients | 4/170 | 2.4% | |
| Spain (Barcelona) | Sopena | 1999 | 1994–1996 | Emergency room | 4/392 | 1% | |
| Spain (Barcelona) | Ruiz | 1999 | 1996–1997 | In hospital | 6/395 | 1.5% | |
| Spain(13 Spanish hospitals) | Sahuquillo-Arce JM | 2016 | 2005–2007 | In hospital | 51/4304 | 1.2% | |
| Spain (Navarra) | Carrillo de Albornoz | 1991 | 1988 | Emergency room | 18/225 | 8% | |
| Spain (Bilbao) | Obradillo | 1989 | 1982–1986 | Community | 31/164 | 18.8% | |
| Greece (Northern) | Alexiou-Daniil | 1990 | 1990 | Atypical pneumonias | 170/3686 | 4.7% | |
| Italy (San Patrignano) | Boschini | 1996 | 1991–1994 | Community in IDUs | 3/210 | 1.4% | |
| Germany | Schack | 2014 | 2005 | In hospital | 9/255 | 3.5% | |
| Israel (Beer-Sheva) | Lieberman | 1995 | 1991–1992 | In hospital | 20/346 | 5.8% | |
| Israel (Afula) | Shibli | 2010 | 2006–2007 | In hospital | 8/126 | 6.3% | |
| North America | Canada (Halifax) | Marrie | 1996 | 199–1994 | Community | 4/149 | 2.7% |
| Canada (Halifax) | Marrie | 1989 | 1981–1987 | In hospital | 22/588 | 3.7% | |
| USA (Pittsburg) | Fang | 1990 | 1986–1987 | In hospital | 0/359 | 0% | |
| USA (5 hospitals Chicago and Nashville) | Jain | 2015 | 2010–2012 | In hospital | 0/2259 | 0% | |
| USA (Maryland) | Mundy | 1995 | 1990–1991 | In hospital | 0/385 | 0% | |
| Latin America | French Guiana (Cayenne) | Epelboin | 2012 | 2004–2007 | In hospital | 32/131 | 24.4% |
| French Guiana (Cayenne) | Epelboin (this study) | 2020 | 2008–2012 | In hospital | 106/275 | 38.0% | |
| Chile (Santiago) | Diaz | 2007 | 2003–2005 | In hospital | 0/176 | 0% | |
| Argentina (Buenos Aires) | Luna | 2011 | 1997–1998 | Emergency room and community | 1/346 | 0.3% | |
| Brazil (Montenegro) | Bahlis | 2018 | 2014–2015 | In hospital | 0/459 | 0% | |
| Brazil 5 countries of South America (Mexico, Chile, Argentina, Uruguay, Brazil) | Jardim | 2003 | 1997–1998 | In hospital | 0/84 | 0% | |
| Guatemala (Cuilapa and Quetzaltenango) | Contreras | 2015 | 2008–2012 | In hospital | 0/188 | 0% | |
| Asia | Singapore | Chiang | 2007 | 3 years (NK) | In hospital children | 0/1702 | 0% |
| India | Panjwani | 2015 | To 2015 | Littérature review | 0% | ||
| India (Bangalore) | Raj Gangoliya | 2016 | 2014–2015 | Atypical pneumonia | 2/77 | 2.5% | |
| Taiwan | Lai | 2014 | 2012–2013 | In hospital | 0/166 | 0% | |
| China (Nanjing) | Chen | 2014 | 2011–2013 | In hospital children | 1/1204 | 0.08% | |
| China (Guangzhou) | Lin | 2015 | 2011–2012 | In hospital children | 26/20160 | 0.13% | |
| China (Wuhan) | Liu | 2015 | 2010–2012 | In hospital children | 21/39756 | 0.05% | |
| China (Hubei) | Wu | 2014 | 2010–2012 | In hospital children | 42/10435 | 0.4% | |
| Japan (Okayama) | Okimoto | 2004 | 2001–2003 | In hospital | 4/284 | 1.4% | |
| Oceania | New Zealand (Waikato) | Karalus | 1991 | 1988 | In hospital | 0/92 | 0% |
| New Zealand (Christchurch) | Neill | 1996 | 1992–1993 | In hospital | 0/255 | 0% | |
| Australia (Adelaide) | Lim | 1989 | In hospital | 0/106 | 0% | ||
| Africa | Cameroon (Yaounde) | Koulla-Shiro | 1996 and 1997 | 1991–1993 | In hospital | 6/91 | 6.5% |
| South Africa (Cape Town) | Maartens | 1994 | 1987–1988 | In hospital | 0/92 | 0% |
COPD = chronic obstructive pulmonary disease; ICU = intensive care unit; IDUs = intravenous drug users; NK = not known; UK = United Kingdom; USA = United States of America; BTS = British Thoracic Society; SPILF = Société de Pathologie Infectieuse de Langue Française.
Data from the different recommendations: Société de Pathologie Infectieuse de Langue Française 1991 updated 2000; Agence française de sécurité sanitaire des produits de santé 2005.